I agree that this site is using cookies. You can find further informations here.
X
Uchibori, Ken
92  results:
Search for persons X
?
1

Distinction of ALK fusion gene‐ and EGFR mutation‐positive ..:

Akita, Takahiro ; Ariyasu, Ryo ; Kakuto, Sho...
Thoracic Cancer.  15 (2024)  10 - p. 788-796 , 2024
Link: https://doi.org/10.1111/..
 
?
2

A macrocyclic kinase inhibitor overcomes triple resistant m..:

Suzuki, Mai ; Uchibori, Ken ; Oh-hara, Tomoko...
npj Precision Oncology.  8 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
3

Efficacy of osimertinib in patients with EGFR‐mutation posi..:

Kiritani, Ayu ; Amino, Yoshiaki ; Uchibori, Ken...
Thoracic Cancer.  , 2024
Link: https://doi.org/10.1111/..
 
?
4

3D layered co-culture model enhances Trastuzumab Deruxtecan..:

Shiraishi, Akari ; Oh-hara, Tomoko ; Takahashi, Yuki...
Biochemical and Biophysical Research Communications.  725 (2024)  - p. 150255 , 2024
Link: https://doi.org/10.1016/..
 
?
5

MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCL..:

Kondo, Nobuyuki ; Utsumi, Takahiro ; Shimizu, Yuki...
JCI Insight.  8 (2023)  24 - p. , 2023
Link: https://doi.org/10.1172/..
 
?
6

Real-World Outcome Analysis of Patients With Stage IV NSCLC..:

Ariyasu, Ryo ; Kakuto, Sho ; Miyadera, Keiki...
JTO Clinical and Research Reports.  4 (2023)  6 - p. 100524 , 2023
Link: https://doi.org/10.1016/..
 
?
7

Clinical characteristics of patients with KRAS mutation det..:

Amino, Yoshiaki ; Low, Siew‐Kee ; Ninomiya, Hironori...
Thoracic Cancer.  14 (2023)  33 - p. 3317-3322 , 2023
Link: https://doi.org/10.1111/..
 
?
8

Soluble interleukin-2 receptor as a predictive biomarker fo..:

Tozuka, Takehiro ; Yanagitani, Noriko ; Yoshida, Hiroshi...
Investigational New Drugs.  41 (2023)  3 - p. 411-420 , 2023
Link: https://doi.org/10.1007/..
 
?
9

A phase II feasibility study of carboplatin and nab‐paclita..:

Sakashita, Hiroyuki ; Uchibori, Ken ; Jin, Yasuto...
Thoracic Cancer.  13 (2022)  9 - p. 1267-1275 , 2022
Link: https://doi.org/10.1111/..
 
?
10

EGFR-Mutated Pulmonary Choriocarcinoma Combined With Adenoc..:

Shigematsu, Yasuyuki ; Nakano, Kaoru ; Uchibori, Ken.
Journal of Thoracic Oncology.  17 (2022)  11 - p. 1318-1322 , 2022
Link: https://doi.org/10.1016/..
 
?
11

GSK3 inhibition circumvents and overcomes acquired lorlatin..:

Shimizu, Yuki ; Okada, Koutaroh ; Adachi, Jun...
npj Precision Oncology.  6 (2022)  1 - p. , 2022
Link: https://doi.org/10.1038/..
 
?
12

EGFR-TKI re-administration after osimertinib failure in T79..:

Ogusu, Shinsuke ; Ariyasu, Ryo ; Akita, Takahiro...
Investigational New Drugs.  40 (2022)  6 - p. 1342-1349 , 2022
Link: https://doi.org/10.1007/..
 
?
13

Soluble PD-L1 works as a decoy in lung cancer immunotherapy..:

Sagawa, Ray ; Sakata, Seiji ; Gong, Bo...
JCI Insight.  7 (2022)  1 - p. , 2022
Link: https://doi.org/10.1172/..
 
?
14

Comparison of salvage surgeries for lung adenocarcinoma tre..:

Iwamoto, Naoya ; Matsuura, Yosuke ; Ninomiya, Hironori...
Current Problems in Cancer: Case Reports.  4 (2021)  - p. 100089 , 2021
Link: https://doi.org/10.1016/..
 
?
15

Characteristics of central nervous system progression in no..:

Sakamoto, Hiroaki ; Yanagitani, Noriko ; Manabe, Ryo...
Cancer Reports.  4 (2021)  6 - p. , 2021
Link: https://doi.org/10.1002/..
 
1-15